Search Results pe patients
1.
Transcatheter Amplatzer Device Closure of Atrial Septal Defect and Patent Foramen Ovale in Patients With Presumed Paradoxical Embolism
...Amplatzer septal occluder (ASO) used to close PFO and/or atrial septal defect (ASD) in patients with paradoxical embolism (PE). * Patients and Methods: Between April 1998 and November 2002, 103 patients at the Mayo Clinic in Rochester, Minn, and Scottsdale...
January 1, 2004; Mayo Clinic Proceedings
2.
Using Ultrasound to Clarify a Nondiagnostic V/Q Scan.(ventilation-perfusion )
...associates evaluated the diagnostic utility of the lower extremity Doppler ultrasound scan in outpatients with suspected PE. Patients with suspected PE but nondiagnostic V/Q scans followed by venous compression ultrasound examination of the lower extremities...
December 15, 2000; American Family Physician
3.
NexMed Reports Pilot Study Results for the Treatment of Premature Ejaculation at AUA Annual Meeting.
...This AUA event is the premier meeting in urology with over 10,000 urologists attending from around the world. Fifty-one PE patients (mean age 37.7 years and PE duration of 4.5 years) were recruited in a 3-month, multi-center, single-blind, study. Eight...
April 24, 2003; PR Newswire
4.
NexMed Continues Development of Proprietary Treatment For Premature Ejaculation.
...American Urological Association, NexMed conducted a three-month, multi-center, single-blind pilot study for which fifty-one PE patients (mean age 37.7 years and PE duration of 4.5 years) were recruited. Eight patients were enrolled in the control (alprostadil...
July 15, 2003; PR Newswire
5.
NexMed's Progress in Premature Ejaculation Studies Reported In September Issue of Biotech Business; - Company Discussed Strong Cash Position and Progress in ED Therapy During Q2 Conference Call -.
...results of which were presented at the 2003 Annual Meeting of the American Urological Association. Of the fifty-one PE patients (mean age 37.7 years and PE duration of 4.5 years) recruited for the study, eight were enrolled in the control (alprostadil...
August 21, 2003; PR Newswire
6.
NEXMED DEVELOPING TREATMENT FOR PREMATURE EJACULATION.
...American Urological Association, NexMed conducted a three-month, multi-center, single-blind pilot study for which fifty-one PE patients (mean age 37.7 years and PE duration of 4.5 years) were recruited. Eight patients were enrolled in the control (alprostadil...
September 1, 2003; Biotech Business
7.
VIVUS INITIATES PREMATURE EJACULATION CLINICAL TRIAL.
...Development at VIVUS. Today, there is no approved medical therapy for the treatment of PE, even though some experts believe PE patients constitute the largest subset of patients with sexual dysfunction. VIVUS, Inc. is a pharmaceutical company engaged in...
January 1, 2003; Biotech Business
8.
Thromboprophylaxis Does Not Protect Severely Injured Patients Against Pulmonary Embolism
...injury type and severity, operations, and mortality. Thromboprophylaxis was used with equal frequency between PE and no-PE patients (71% vs 80%, P = 0.4). The type of prophylaxis used was similar between patients with PE (17% heparin, 71% sequential...
October 1, 2004; The American Surgeon
9.
VIVUS Announces Initiation of Premature Ejaculation Clinical Trial.
...Development at VIVUS. Today, there is no approved medical therapy for the treatment of PE, even though some experts believe PE patients constitute the largest subset of patients with sexual dysfunction. VIVUS, Inc. is a pharmaceutical company engaged in...
November 20, 2002; Business Wire
10.
A Blood-thinner Administered Once Daily Prevents DVT Among Hospitalized Patients; Largest Clinical Study of its Kind Shows that Almost Half of the Complications and Deaths Due to in-Hospital DVT Can be Prevented with Once Daily Dalteparin Administration.
...According to the study's senior investigator, BWH's Samuel Z. Goldhaber, MD, a cardiologist who specializes in DVT and PE, Patients who fit the profile -- including those with cancer, respiratory and congestive heart failure -- should be considered...
August 17, 2004; PR Newswire
|
